Drugs / Peginterferon alfa-b2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04517539 | Dec 2020 → Dec 2022 | thymic epithelial neoplasm | Shanghai Cancer Hospital, China | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon alfa-b2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04517539 ↗ |
| Known as | Peginterferon alfa-2b | “Peginterferon alfa-2b is safe, effective in the treatment of patients with metastatic thymic epithelial tumors.” NCT04517539 ↗ |
| Modality | Protein / enzyme biologic | “Peginterferon alfa-2b” NCT04517539 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of Peginterferon alfa-b2(90ug)” NCT04517539 ↗ |